Sam Brusco, Associate Editor04.18.23
Remote patient monitoring (RPM) solutions company Tenovi launched its cellular-enabled remote Peak Expiratory Flow Meter (PFM). When paired with the company’s Cellular Gateway, the device lets asthma patients transmit peak expiratory flow rate (PEF) and one-second forced expiratory volume (FEV1) readings instantly to doctors.
Traditional peak flow monitoring measure PEF, a key indicator of lung function for asthma patients. However, these devices need manual recording and tracking of readings, which are typically only accessible to a provider during an office visit.
This makes remote monitoring of asthmatic patient parameters quite desirable because it lets providers view patient data in real-time, allowing for early intervention and better management of the condition.
"Today's release of Tenovi's cellular-based peak flow meter is a major milestone as it empowers physicians to provide better patient care and allows for significantly better patient adherence compared to the alternatives in the market," Nizan Friedman, PhD., founder and CEO of Tenovi, told the press.
Clinical research has shown measuring FEV1 is the gold standard to monitor lung function. A recent study determined when remotely monitoring FEV1 measurements, asthma patients showed improved outcomes among patients with respiratory illness.
Tenovi serves as the data aggregation, data automation, and fulfillment arm for remote patient monitoring companies.
"We are committed to continuing offering the most advanced RPM solutions to our telehealth, chronic care, software, and RPM service company partners," said Friedman.
Traditional peak flow monitoring measure PEF, a key indicator of lung function for asthma patients. However, these devices need manual recording and tracking of readings, which are typically only accessible to a provider during an office visit.
This makes remote monitoring of asthmatic patient parameters quite desirable because it lets providers view patient data in real-time, allowing for early intervention and better management of the condition.
"Today's release of Tenovi's cellular-based peak flow meter is a major milestone as it empowers physicians to provide better patient care and allows for significantly better patient adherence compared to the alternatives in the market," Nizan Friedman, PhD., founder and CEO of Tenovi, told the press.
Clinical research has shown measuring FEV1 is the gold standard to monitor lung function. A recent study determined when remotely monitoring FEV1 measurements, asthma patients showed improved outcomes among patients with respiratory illness.
Tenovi serves as the data aggregation, data automation, and fulfillment arm for remote patient monitoring companies.
"We are committed to continuing offering the most advanced RPM solutions to our telehealth, chronic care, software, and RPM service company partners," said Friedman.